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osting by EAbstract A simple, rapid, accurate, precise and sensitive spectrophotometric method for the deter-
mination of amlodipine besylate (ADB) in bulk sample and in dosage forms is described. The
method is based on oxidation of the drug by potassium permanganate in acidic medium and deter-
mine the unreacted oxidant by measuring the decrease in absorbance for ﬁve different dyes; meth-
ylene blue (MB), acid blue 74 (AB), acid red 73 (AR), amaranth dye (AM) and acid orange 7 (AO)
at a suitable kmax 663, 609, 511, 520, and 484 nm, respectively. Regression analysis of Beer’s law
plots showed good correlation in the concentration ranges 1.0–24, 0.9–22, 1.2–26, 0.9–12.8 and
1.0–14 lg ml1, respectively. The apparent molar absorptivity, Sandell sensitivity, detection and
quantitation limits were calculated. For more accurate results, Ringbom optimum concentration
ranges were 1.2–22.4, 1.1–20, 1.4–24.5, 1.0–12.3 and 1.3–13.2 lg ml1, respectively. Statistical treat-
ment of the results reﬂects that the proposed procedures are precise, accurate and easily applicable
for the determination of amlodipine besylate in pure form and in pharmaceutical preparations.
ª 2009 King Saud University. All rights reserved.1. Introduction
Amlodipine besylate is 2-[(2-aminoethoxy) methyl]-4-(2-chloro-
phenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxy-late-3-ethyl-
5-methyl ester mono-benzene sulphonate. It is a new calciumm (A.S. Amin).
ity. All rights reserved. Peer-
d University.
lsevierchannel-blocking agent with vasodilator activity similar to that
of nifedipine (Reynolds, 1996). It is mainly used for its antian-
ginal, antihypertensive and antiarrhythic activity. The drug in
pure form and its formulations are not ofﬁcial in USP pharma-
copoeia, and therefore require much more investigation.
Different analytical methods that have been reported for its
determination including, high-performance liquid chromatog-
raphy (Baranda et al., 2004, 2005; Sudhakar et al., 2006; Zarghia
et al., 2005; Josefsson et al., 1995; Naidu et al., 2005; Avadhanul
et al., 1996; Sankar et al., 1997), liquid chromatography coupled
with tandemmass spectrometry (Yasuda et al., 1996), gas liquid
chromatography (Bersford et al., 1987), gas chromatography
coupled with mass spectrometry (Feng et al., 1998), high-per-
formance thin layer liquid chromatography (Chandrashekhar
et al., 1994; Pandya et al., 1995; Ilango et al., 1997) high-
performance capillary electrophoresis (Jiang et al., 2003) and
60 S.A. Shama et al.ﬂuorimetry (Mohamed et al., 1998). Visible spectrophotometric
methods are commonly used in industrial laboratories because
of their simplicity, selectivity and sensitivity. The amlodipine
besylate in pharmaceutical preparations was determined by
the spectrophotometric method (Sridhar et al., 1997; Rahman
et al., 2004) involving oxidation of the drug, voltammetrically
(Gazy, 2004). A number of other extractive spectrophotometric
methods (Lokesh et al., 1996; Reddy et al., 1997; Singhvi and
Chaturvedi,1998, 1999; Rahman and Azmi,2000, 2001; Prabha-
kan and Giridhar, 2002) have been also reported. However,
some of these methods are somewhat tedious and time consum-
ing. Therefore, the need for a fast, low cost, accurate, precise
and sensitive method is obvious, especially for a routine quality
control analysis of pharmaceutical products containing ADB.
All ﬁve dyes, methylene blue (MB), basic blue 9 [122965-43-
9]; acid blue 74 (AB 74), indigocarmine, indigo-5,50-disulfo-
nonic acid disodium salt [860-22-0]; acid red 73 (AR 73), bril-
liant crocein MOO C.I. 27290; amaranth (AM), acid red 27,
azorubin S, [915-67-3] and acid orange 7, (AO), orange II so-
dium salt [633-96-5] are well known for their high absorptivity
and have been utilized for estimation of excess oxidant. The
work aims to demonstrate a simple, rapid, accurate, precise
and sensitive spectrophotometric method suitable and conve-
nient for the determination of amlodipine besylate in pure
and in dosage forms.2. Experimental
2.1. Apparatus
All the absorption spectral measurement were made using
JASCO V-530 (UV–VIS) spectrophotometer (Japan), with
scanning speed 400 nm min1 and band width 2.0 nm,
equipped with 10 mm matched quartz cells.
2.2. Reagents
All chemicals used were of analytical or pharmacopoeial grade
purity and bidistilled water was used. Standard amlodipine
besylate was obtained fromEgyptian International Pharmaceu-
tical Industries Co. (EIPICO) 10th of Ramadan City, Egypt.
Stock amlodipine besylate solution (100 lg ml1) was prepared
by dissolving 0.01 g in bidistilled water and adjusted to 100 ml
with bidistilled water in 100 ml measuring ﬂask. Working solu-
tions of lower concentration were prepared by serial dilutions.
Aqueous solutions of 103 M AB (Merck), and AO, AM
and AR (Aldrich), or 104 M for MB (Merck) were prepared
by dissolving an appropriate weight in 100 ml bidistilled water.
A stock (5.0 · 104 M) solution of KMnO4 (Aldrich), was
freshly prepared by dissolving an accurate weight in bidistilled
water, and standardized as recommended (Basset et al., 1986).
A solution of 0.2 M H2SO4, was prepared by adding exact
volume from stock (98%) concentrated acid to bidistilled
water, cooled to room temperature, transferred to 500 ml mea-
suring ﬂask, diluted to the mark and standardized as recorded
(Basset et al., 1978).2.3. General procedure
The method depends on oxidation of amlodipine besylate by
addition of 0.1–2.6 ml ADB (100 lg ml1) to 1.0 ml of5.0 · 104 M KMnO4 and 1.0 ml of 0.2 M H2SO4. The solu-
tion was heated in a water bath at 50 ± 1 C for 10 min, the
mixture was cooled and 2.0 ml (104 M) of MB, 0.8, 0.35,
0.8 and 0.7 ml (103 M) of AB, AR, AM and AO, respectively,
was added. The volume was completed to 10 ml with bidistilled
water. The decrease in color intensity of dyes were measured
spectrophotometrically against a blank solution containing
the same constituent except drug treated similarly, at their cor-
responding kmax 663, 609, 511, 520 or 484 nm, respectively.
The concentration range was determined in each case by
plotting the concentration of amlodipine besylate against
absorbance at the corresponding maximum wavelengths.
2.4. Procedure for determination of dosage forms
At least ten tablets of ADB were weighed into a small dish,
powdered and mixed well. A portion equivalent to 10 mg
was weighed and dissolved in 100 ml bidistilled water, mixed
well for 15 min using a magnetic stirrer and ﬁltered through
a sintered glass crucible G4. A 1.0 ml aliquot of the test solu-
tion (100 lg ml1 of ADB) was treated as described above in
the general procedure.
3. Results and discussion
An analytical procedure based on the speciﬁc reactivity of an
amino group was investigated. The method involves two steps
namely:
(1) Oxidation of amlodipine besylate with KMnO4 in acidic
medium by heating in water bath of 50 ± 1 C.
(2) Determination of unreacted oxidant by measuring the
decrease in absorbance of dyes at a suitable kmax.4. Optimization
The inﬂuence of each of the following variables on the reaction
was tested.
4.1. Effect of permanganate concentration
The inﬂuence of KMnO4 concentration was studied in the
range from 105 to 104 M, as ﬁnal concentration. The opti-
mum results were obtained with 5.0 · 105 M; higher concen-
tration of KMnO4 caused the color to disturbed.
4.2. Effect of acid concentration
Different types of acid were examined (HCl, H2SO4, H3PO4,
CH3COOH and HNO3). The most suitable acid to achieve
maximum yield of redox reaction was found to be sulphuric
acid. Moreover, various volumes of H2SO4 were tested and
found to be 1.0 ml of 0.2 M as shown in Fig. 1.
4.3. Effect of temperature and time
The oxidation process of amlodipine besylate is catalyzed by
heating in water bath of 50 ± 1 C. The time required to
complete the reaction is 10 min. After oxidation process, the
solution must be cooled at least for 3.0 min before addition
of dye.
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Figure 1 Effect of ml added of sulphuric acid (0.2 M) on
absorbance of 10 lg ml1 of amlodipine besylate with KMnO4
(5.0 · 104 M) and dyes (1.0 · 103 M) except on using methylene
blue (1.0 · 104 M).
Table 1 Optical and regression characteristics of amlodipine besyla
Parameters MB AB
kmax (nm) 663 609
Beer’s law limits (lg ml1) 1.0–24 0.9–22
Ringbom limits (lg ml1) 1.2–22.4 1.1–20
Molar absorptivity (L mol1 cm1) 2.25 · 104 3.12 · 1
Sandell sensitivity (ng cm2) 25.19 18.15
Detection limits (lg ml1) 0.277 0.249
Quantitation limits (lg ml1) 0.923 0.831
Regression equation\: slope (b) 0.0397 0.0551
Intercept (a) 5.3 · 103 8.5 · 10
Correlation coeﬃcient (r) 0.9998 0.9999
RSD**% 0.66 1.01
* With respect to A= a+ bC where C is concentration of drug in lg m
** Relative standard deviation for six determinations.
Table 2 Evaluation of the accuracy and precision of the proposed
Dye Taken (lg ml1) Recovery (%)
MB 8.0 100.1
10 100.2
12 99.9
AB 8.0 99.8
10 100.5
12 99.7
AR 8.0 100.3
10 99.6
12 99.8
AM 8.0 99.5
10 99.9
12 100.3
AO 8.0 100.4
10 100.6
12 100.6
a Relative standard deviation for six determinations.
b Relative error.
c 95% conﬁdence limits and ﬁve degrees of freedom.
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The optimum volume of dye used for production of maximum
color intensity is 2.0 ml of 104 M MB, or 0.8, 0.35, 0.8 and
0.7 ml of 103 M AB, AR, AM and AO, respectively. The ef-
fect of time after the addition of dye indicated that shaking for
1.0 min is sufﬁcient to give reliable results for all dyes. The col-
or remains constant for at least 48 h.
4.5. Analytical data
Beer’s law limits, molar absorptivities, Sandell sensitivities,
regression equations and correlation coefﬁcients were calcu-
lated and recorded in Table 1. The limits of detection
(K= 3) and quantitation (K= 10) were established according
to IUPAC deﬁnitions (IUPAC, 1978) and recorded in Table 1.
In order to determine the accuracy and precision of thete with ﬁve different dyes.
AR AM AO
511 520 484
1.2–26 0.9–12.8 1.0–14
1.4–24.5 1.0–12.3 1.3–13.2
04 2.01 · 104 22 · 104 3.42 · 104
28.17 13.44 16.58
0.329 0.239 0.272
1.096 0.798 0.907
0.0355 0.0744 0.0603
3 9.9 · 103 4.6 · 103 3.1 · 103
0.9998 0.9996 0.9999
0.82 0.51 0.73
l1 and A is absorbance.
procedure of amlodipine besylate.
RSDa (%) REb (%) Conﬁdence limitsc
0.86 0.90 8.01 ± 0.0724
0.89 0.93 10.02 ± 0.0933
0.53 0.55 11.99 ± 0.0661
0.74 0.78 7.98 ± 0.0619
0.46 0.48 10.05 ± 0.0483
0.38 0.39 11.96 ± 0.0472
0.65 0.68 8.02 ± 0.0546
0.71 0.95 9.96 ± 0.0745
0.40 0.42 11.98 ± 0.0504
0.70 0.74 7.96 ± 0.0588
0.88 0.92 9.99 ± 0.0923
0.67 0.71 12.04 ± 0.0850
0.80 0.84 8.03 ± 0.0672
0.77 0.80 10.06 ± 0.0808
0.33 0.34 12.07 ± 0.0409
Table 3 Determination of ADB in pharmaceutical formulations using the proposed and ofﬁcial methods.
Pharmaceutical formulations Proposed methods
MB AB AR
Recovery (%) t-value* F-ratio* Recovery (%) t-value* F-ratio* Recovery (%) t-value* F-ratio*
Norvasc 5 mga 99.2 0.27 1.36 99.8 0.58 2.11 100.1 0.82 2.85
Amilo 5 mgb 100.2 1.02 3.12 99.6 0.80 2.69 100.4 0.62 1.84
Alkapress 5 mgc 99.8 0.58 1.45 100.1 0.62 2.11 99.6 0.36 1.14
Amlodipin 5 mgd 100.5 0.19 1.21 99.6 0.37 1.27 99.7 0.34 1.64
Myodura 5 mge 100.3 0.92 1.58 99.8 0.36 1.89 99.6 0.64 1.91
Oﬃcial
AM AO Recovery (%) Recovery (%)
Recovery (%) t-value* F-ratio* Recovery (%) t-value* F-ratio*
Norvasc 5 mga 99.5 0.90 2.58 99.7 0.57 1.89 100.1 98.9
Amilo 5 mgb 99.9 0.15 1.27 99.7 1.08 2.93 100.4 99.4
Alkapress 5 mgc 100.4 0.48 2.12 99.7 0.54 1.58 99.6 99.5
Amlodipin 5 mgd 99.8 0.39 1.77 100.2 0.95 1.89 99.7 99.4
Myodura 5 mge 99.5 0.54 1.85 100.1 0.34 2.11 99.6 99.4
a Pﬁzer S.A.E. Cairo, Egypt under authority of Inc., USA.
b Alpha Chem Advanced of Pharmaceutical Industries Company (ACAPI), Bader Industrial City, Cairo, Egypt.
c Alkan Pharmaceutical Company, Cairo, Egypt.
d Pharaonia Pharmaceutical, Pharo-pharma Company, Cairo, Egypt.
e Global Napi Pharmaceuticals Company (GNP) under license from Merck & Co. Inc., USA, Egypt.
* Theoretical value for t- and F-values for ﬁve degrees of freedom and 95% conﬁdence limits are 2.57 and 5.05, respectively.
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ADB were prepared and analyzed in six replicates. The analyt-
ical results obtained from this investigation were summarized
in Table 2.
5. Interference
A systematic quantitative study was undertaken by measuring
the absorbance of solutions containing 10 lg ml1 of ADB
with varying concentration of the additives and excipients such
as calcium hydrogen phosphate, magnesium stearate and
starch. Under the experimental conditions, the effect of excip-
ients frequently found in formulations was evaluated using the
proposed method. The additives and excipients in all tablets
are not interfere.
6. Analytical applications
The proposed method was successfully applied to determine
ADB in its dosage forms. The results obtained were compared
statistically by Student’s t-test (for accuracy), and variance ra-
tio F-test (for precision) (Miller and Miller, 1993), with the
ofﬁcial method (British Pharmacopoeia (BP), 2005) at 95%
conﬁdence level as recorded in Table 3. The results showed
that the t- and F-values were lower than the critical values
indicating that there was no signiﬁcant difference between
the proposed and ofﬁcial methods. The proposed method
was more accurate with high recoveries compared to the
ofﬁcial method (depended on liquid chromatography using
stationary phase, octadecylsilyl silica gel 5.0 lm and mobile
phase, mix 15 volumes of acetonitrile, 35 volumes of methanol
and 50 volumes of a solution prepared as follows: dissolve
7.0 ml of triethylamine in 1000 ml bidistilled water and adjustto pH 3.0 ± 0.1 with phosphoric acid), so the proposed meth-
od can be recommended for routine analysis of ADB in pure
and dosage forms in the majority of drug quality control
laboratorie.
7. Conclusion
The proposed method was advantageous over other reported
visible spectrophotometric and colorimetric methods, related
to their high reproducibility, high sensitivity, less time consum-
ing and using simple and inexpensive reagents. Moreover, this
method allowed the determination of ADB up to 0.9 lg ml1,
in addition to simplicity, rapidity, precision and stability of
colored species for more than 48 h. The proposed method
may be applied for routine analysis and in quality control lab-
oratories for the quantitative determination of the ADB in raw
materials and in pharmaceutical formulations. The stability
constant was determined and the free energy change was calcu-
lated potentiometrically. The positive value of DG reveals that
the dissociation of this drug is not spontaneous.
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